Our group has investigated SARS-CoV-2 infection in different areas. We have performed clinical validation of different diagnostic tests, evaluating the analytical validity of different diagnostic devices in real life and helping their correct positioning as diagnostic tools. We have investigated the analysis of adaptive immunity T and B in special groups of patients such as: patients with hematological diseases, patients with rheumatological diseases treated with biological drugs, patients with kidney disease undergoing transplantation, hemodialysis or peritoneal dialysis and elderly patient resident in health institutions. Also, we have studied the neutralizing capacity of patient serum in cell culture in order to predict disease severity based on clinical and virological parameters. This line of research has public funding (PI21/00563) for health research. More than 50 articles have been published in international journals and collaboration has been carried out with different groups such as the Institute of Integrative Systems Biology (I2SysBio) of the University of Valencia, the Center for Epidemiological Surveillance of the Foundation for the Promotion of Sanitary and Biomedical Research (FISABIO), the Department of Physical Chemistry of the University of Valencia, the Institute of Agrochemistry and Food Technology (IATA-CSIC) or the Research Institute of the Hospital 12 de Octubre in Madrid We also also aim to integrate NGS in the diagnosis, management and surveillance of SARS-CoV-2